T1	SectionAnnotate 628 654	History of Present Illness
T2	SectionSkip 2268 2762	Current Outpatient Medications   Medication Instructions    amLODIPine (NORVASC) 5 mg, Oral, Daily Scheduled    atorvastatin (LIPITOR) 20 mg, Oral, Daily Scheduled    famotidine (PEPCID) 20 mg, Oral, 2 Times Daily PRN    losartan (COZAAR) 50 mg, Oral, Daily Scheduled    metFORMIN (GLUCOPHAGE) 500 mg, Oral, Daily With Breakfast Scheduled    OYSTER SHELL CALCIUM-VIT D3 500 mg(1,250mg) -200 unit tablet 1 tablet, Oral, 2 times daily    polyethylene glycol (MIRALAX) 17 g, Oral, Daily PRN
T3	SectionAnnotate 2824 2839	FAMILY HISTORY:
T4	SectionAnnotate 2909 2936	PERSONAL AND SOCIAL HISTORY
T5	SectionSkip 3190 3957	PHYSICAL EXAM via video observation:   Vitals: Not performed as today's visit was conducted via video  Constitutional: Ill-appearing. Not diaphoretic.  Head: Normocephalic, atraumatic. External ears normal. Nose normal.    Eyes: Extraocular movements intact. Conjunctivae normal. No eye discharge. Cannot appreciate scleral icterus.  Neck: Normal range of motion.   Pulmonary/Chest: Normal effort. No respiratory distress. No cough.  GI: No abdominal distention.   Musculoskeletal: No apparent edema.   Skin: Not jaundiced. Not pale. No visible erythema. No visible rash.  Neurological: Alert and oriented to person, place and time. Able to stand from sitting and walk.   Psychiatric: Normal mood and affect. Behavior is 
 normal. Judgment and thought content normal.
T6	SectionSkip 3966 4041	Relevant Diagnostic Studies:    Most recent labs notable for the following:
T7	SectionSkip 4045 4667	Lab Results   Component Value Date    WBC Count 10.8 (H) 07/20/2021    Neutrophil Absolute Count 8.26 (H) 07/20/2021    Hemoglobin 9.9 (L) 07/20/2021    Hematocrit 32.4 (L) 07/20/2021    Platelet Count 315 07/20/2021    Creatinine 0.54 (L) 07/20/2021    Bilirubin, Total 4.5 (H) 07/20/2021    Alkaline Phosphatase 787 (H) 07/20/2021    AST 66 (H) 07/20/2021    Alanine transaminase 83 (H) 07/20/2021    Albumin, Serum / Plasma 2.6 (L) 07/20/2021    Int'l Normaliz Ratio 1.3 (H) 07/20/2021    Sodium, Serum / Plasma 136 07/20/2021    Potassium, Serum / Plasma 3.6 07/20/2021    Calcium, total, Serum / Plasma 9.3 07/20/2021
T8	SectionSkip 4674 4959	Lab Results   Component Value Date    Cancer Antigen 19-9 1,041 (H) 06/27/2021         I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:    Result Date: 07/18/2021  CT ABDOMEN/PELVIS
T9	SectionSkip 4961 7378	FINDINGS:  Visualized lung bases:  Bibasilar atelectasis    Liver:  Slightly increased size of some of the hypoattenuating/hypoenhancing lesions in the liver. Other lesions are not significant changed. Index lesions as below.    INDEX LESIONS (Restaging):   AI1:  Hepatic segment 5 lesion : 1.7 x 1.3 cm (Se/Im September 43), previously 1.7 x 1.3 cm   AI2:  Hepatic segment 6 lesion : 0.9 x 0.7 cm (Se/Im September 53), previously 0.4 x 0.3 cm   AI3:  Hepatic segment December 23 lesion : 1.0 x 0.9 cm (Se/Im September 39), previously 0.7 x 0.4 cm     Additionally, a few new small lesions, for example the lesion in hepatic segment 5 measuring up to 0.8 cm (series 3 image 47).    Gallbladder/bile ducts: Distended gallbladder measuring up to 4.7 cm in diameter, but without significant associated inflammatory changes.    New mild intrahepatic/extra hepatic biliary ductal dilatation with abrupt caliber change at the mass 
 centered in the pancreaticoduodenal groove.    Spleen:  Unremarkable    Pancreas:  Increased size of the heterogeneously enhancing mass centered in the pancreaticoduodenal groove, now measuring approximately 4.5 cm x 3.7 cm x 7.5 cm (series 3 image 71, series 602 image 55). Mass extends into the distal aspects of the common bile duct (series 602 image 55). Increased associated mild pancreatic ductal dilatation.    New mild peripancreatic fat stranding and mild pancreatic parenchymal edema throughout the remaining pancreas.     Adrenal Glands:  Similar small left adrenal nodule measuring up to 1.1 cm (series 3 image 41).    Kidneys:  Similar subcentimeter hypoattenuating foci, too small to fully characterize, but likely benign.     GI Tract:  Unremarkable    Vasculature:  Similar atherosclerosis.    Lymphadenopathy: Increased size of multiple upper abdominal and mesenteric lymph nodes, some of which are centrally cystic/necrotic, for example the superior mesenteric lymph node now measuring approximately 1.5 cm x 1.2 cm) series 3 image 78) previously 1.3 cm x 0.9 cm, and the portal caval lymph node now measuring approximately 2.2 cm x 1.2 cm (series 3 image 57) previously 1.4 cm x 0.9 cm.    Peritoneum: No ascites    Bladder: Distended    Reproductive organs: Unremarkable    Bones:  Similar multilevel spondylosis. Similar degenerative changes of the hips, sacroiliac joints, and pelvis.    Extraperitoneal soft tissues: Unremarkable    Lines/drains/medical devices: None
T10	SectionAnnotate 7382 7393	IMPRESSION:
T11	SectionSkip 8019 9696	FINDINGS: Visualized lung bases:  Unremarkable Liver:  At least 6 hepatic metastatic lesions with largest in the gallbladder fossa 2.4 cm (series 8, image 38). Gallbladder: Unremarkable Spleen:  Unremarkable Pancreas: Heterogeneous relatively well-circumscribed mass in the pancreaticoduodenal groove measuring 3 3.7 x 3.4 cm (series 8, image 59). The mass likely represent exophytic pancreatic or exophytic duodenal tumor. No associated pancreatic or biliary ductal dilation. Prominent lymph nodes adjacent to the mass measuring up to 9 mm (series 8, image 57) which is nonspecific but could represent disease involvement. Adrenal Glands:  Indeterminate left adrenal nodule measuring up to 1.1 cm (series 8, image 34). Kidneys:  Likely benign renal cyst in the left inferior pole.    GI Tract:  Mass in the pancreaticoduodenal groove as described above. Nonobstructive bowel. No free air. Vasculature:  Mild to moderate atherosclerotic calcification of the abdominal aorta and its branches. Lymphadenopathy: Prominent mesenteric lymph nodes as described above. Peritoneum: No ascites Bladder: Unremarkable Reproductive organs: Unremarkable Bones:  No suspicious lesion Extraperitoneal soft tissues: Unremarkable Lines/drains/medical devices: None    1.  Heterogeneous relatively well-circumscribed mass in the pancreaticoduodenal groove without associated biliary or pancreatic ductal dilation. Differential diagnoses include neuroendocrine tumor and gastrointestinal stromal tumor. 2.  Aleast 6 hepatic hypoattenuating lesions, with imaging findings suspicious for metastases. 3.  Indeterminate small left adrenal nodule.       Result Date: 06/28/2021  CT CHEST WITH CONTRAST
T12	SectionSkip 9699 10367	FINDINGS: LUNGS: 3 mm lateral left upper lobe nodule (series 
 August 270). A few scattered patchy perihilar bronchovascular groundglass opacities in both upper lobes. PLEURA: No pleural effusion. MEDIASTINUM: No mediastinal lymphadenopathy by CT criteria. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. Normal caliber of the ascending thoracic aorta. Mild coronary calcifications. BONES/SOFT TISSUES: No suspicious osseous lesion.     1. Nonspecific solid 3 mmlateral left upper lobe nodule (series 2 image 100), indeterminate. 2. Few nonspecific patchy peribronchovascular groundglass opacities in the upper lobes, possibly infectious/inflammatory.
T13	SectionAnnotate 10374 10405	Impression and Recommendations:
T14	PROBLEM 488 528	her metastatic pancreatic adenocarcinoma
T15	PROBLEM 755 808	intermittent epigastric and left sided abdominal pain
T16	PROBLEM 821 835	15 lbs wt loss
T17	Symptom 837 845	bloating
T18	Symptom 850 856	nausea
T19	PROBLEM 858 875	acutely worsening
T20	TEST 901 918	Diagnostic workup
T21	TEST 940 971	a CT scan of the abdomen/pelvis
T22	PROBLEM 984 1024	a mass in the pancreaticoduodenal groove
T23	PROBLEM 1037 1077	multiple hepatic hypoattenuating lesions
T24	PROBLEM 1093 1103	metastases
T25	MedicationName 1127 1136	oxycodone
T26	TEST 1158 1180	follow up liver biopsy
T27	PROBLEM 1233 1247	adenocarcinoma
T28	TEST 1256 1259	IHC
T29	PROBLEM 1349 1374	increasing abdominal pain
T30	PROBLEM 1386 1399	elevated LFTs
T31	PROBLEM 1400 1422	mild jaundice symptoms
T32	PROBLEM 1427 1439	sclericterus
T33	TEST 1455 1462	an ERCP
T34	TREATMENT 1507 1554	a 10x80 mm Evolution uncovered bare metal stent
T35	PROBLEM 1563 1603	a high-grade stricture of the distal CBD
T36	TEST 1605 1621	Simultaneous EUS
T37	PROBLEM 1632 1708	a 45.8x44.4mm well circumscribed hypoechoic mass in the head of the pancreas
T38	TEST 1715 1734	additional biopsies
T39	Symptom 1903 1916	a weight loss
T40	PROBLEM 1933 1939	fevers
T41	PROBLEM 1940 1946	chills
T42	MedicationName 1974 1981	Tylenol
T43	PROBLEM 1986 1997	pain relief
T44	TREATMENT 2010 2023	the oxycodone
T45	PROBLEM 2060 2077	some constipation
T46	ClinicalCondition 2119 2122	HTN
T47	ClinicalCondition 2124 2136	Dyslipidemia
T48	ClinicalCondition 2138 2150	Pre-diabetes
T49	ClinicalCondition 2152 2167	Lumbar stenosis
T50	PROBLEM 2168 2189	chronic low back pain
T51	ClinicalCondition 2195 2213	bilateral sciatica
T52	ClinicalCondition 2218 2241	neurogenic claudication
T53	ClinicalCondition 2243 2262	Cervical myelopathy
T54	TREATMENT 2287 2311	Medications   Medication
T55	TREATMENT 2329 2349	amLODIPine (NORVASC)
T56	TREATMENT 2368 2404	Scheduled    atorvastatin (LIPITOR)
T57	TREATMENT 2424 2457	Scheduled    famotidine (PEPCID)
T58	TREATMENT 2493 2510	losartan (COZAAR)
T59	TREATMENT 2530 2566	Scheduled    metFORMIN (GLUCOPHAGE)
T60	TREATMENT 2602 2643	Scheduled    OYSTER SHELL CALCIUM-VIT D3
T61	TREATMENT 2711 2740	polyethylene glycol (MIRALAX)
T62	PROBLEM 2803 2818	Known Allergies
T63	PROBLEM 2854 2882	hereditary pattern of cancer
T64	PROBLEM 3328 3339	diaphoretic
T65	PROBLEM 3363 3373	atraumatic
T66	PROBLEM 3473 3486	eye discharge
T67	PROBLEM 3506 3521	scleral icterus
T68	PROBLEM 3591 3611	respiratory distress
T69	PROBLEM 3616 3621	cough
T70	PROBLEM 3631 3651	abdominal distention
T71	PROBLEM 3675 3689	apparent edema
T72	PROBLEM 3703 3712	jaundiced
T73	PROBLEM 3718 3722	pale
T74	PROBLEM 3727 3743	visible erythema
T75	PROBLEM 3748 3760	visible rash
T76	TEST 4083 4092	WBC Count
T77	TEST 4099 4100	H
T78	TEST 4116 4126	Neutrophil
T79	TEST 4127 4141	Absolute Count
T80	TEST 4165 4175	Hemoglobin
T81	TEST 4198 4208	Hematocrit
T82	TEST 4232 4246	Platelet Count
T83	TEST 4265 4275	Creatinine
T84	TEST 4282 4283	L
T85	TEST 4299 4308	Bilirubin
T86	TEST 4310 4315	Total
T87	TEST 4338 4358	Alkaline Phosphatase
T88	TEST 4381 4384	AST
T89	TEST 4406 4426	Alanine transaminase
T90	TEST 4448 4455	Albumin
T91	TEST 4457 4462	Serum
T92	TEST 4465 4471	Plasma
T93	TEST 4509 4514	Ratio
T94	TEST 4537 4543	Sodium
T95	TEST 4545 4550	Serum
T96	TEST 4553 4559	Plasma
T97	TEST 4578 4587	Potassium
T98	TEST 4589 4594	Serum
T99	TEST 4597 4603	Plasma
T100	TEST 4622 4629	Calcium
T101	TEST 4638 4643	Serum
T102	TEST 4646 4652	Plasma
T103	TEST 4674 4685	Lab Results
T104	TEST 4712 4726	Cancer Antigen
T105	TEST 4799 4837	the patient's relevant imaging studies
T106	TEST 4942 4944	CT
T107	PROBLEM 4996 5017	Bibasilar atelectasis
T108	PROBLEM 5029 5052	Slightly increased size
T109	PROBLEM 5064 5118	the hypoattenuating/hypoenhancing lesions in the liver
T110	PROBLEM 5120 5133	Other lesions
T111	PROBLEM 5163 5176	Index lesions
T112	PROBLEM 5225 5249	Hepatic segment 5 lesion
T113	TEST 5266 5281	Se/Im September
T114	PROBLEM 5319 5343	Hepatic segment 6 lesion
T115	TEST 5360 5375	Se/Im September
T116	PROBLEM 5413 5447	Hepatic segment December 23 lesion
T117	TEST 5464 5479	Se/Im September
T118	PROBLEM 5527 5550	a few new small lesions
T119	PROBLEM 5564 5595	the lesion in hepatic segment 5
T120	PROBLEM 5667 5688	Distended gallbladder
T121	PROBLEM 5737 5780	significant associated inflammatory changes
T122	PROBLEM 5785 5846	New mild intrahepatic/extra hepatic biliary ductal dilatation
T123	PROBLEM 5852 5885	abrupt caliber change at the mass
T124	PROBLEM 5989 6023	the heterogeneously enhancing mass
T125	PROBLEM 6163 6167	Mass
T126	PROBLEM 6247 6301	Increased associated mild pancreatic ductal dilatation
T127	PROBLEM 6306 6343	New mild peripancreatic fat stranding
T128	PROBLEM 6348 6415	mild pancreatic parenchymal edema throughout the remaining pancreas
T129	PROBLEM 6438 6471	Similar small left adrenal nodule
T130	PROBLEM 6529 6571	Similar subcentimeter hypoattenuating foci
T131	PROBLEM 6670 6693	Similar atherosclerosis
T132	PROBLEM 6698 6713	Lymphadenopathy
T133	PROBLEM 6733 6784	multiple upper abdominal and mesenteric lymph nodes
T134	PROBLEM 6804 6829	centrally cystic/necrotic
T135	PROBLEM 6843 6877	the superior mesenteric lymph node
T136	TEST 6974 7001	the portal caval lymph node
T137	PROBLEM 7112 7119	ascites
T138	PROBLEM 7132 7141	Distended
T139	PROBLEM 7190 7220	Similar multilevel spondylosis
T140	PROBLEM 7222 7293	Similar degenerative changes of the hips, sacroiliac joints, and pelvis
T141	TREATMENT 7344 7356	Lines/drains
T142	PROBLEM 7441 7463	the primary malignancy
T143	PROBLEM 7508 7522	Increased size
T144	PROBLEM 7537 7565	hepatic and nodal metastases
T145	PROBLEM 7573 7623	New mild biliary ductal and gallbladder dilatation
T146	PROBLEM 7639 7668	worsening biliary obstruction
T147	PROBLEM 7676 7713	New mild pancreatic ductal dilatation
T148	PROBLEM 7715 7748	mild peripancreatic fat stranding
T149	PROBLEM 7754 7787	mild pancreatic parenchymal edema
T150	PROBLEM 7834 7875	acute interstitial edematous pancreatitis
T151	PROBLEM 7881 7910	pancreatic ductal obstruction
T152	PROBLEM 7918 7951	Similar small left adrenal nodule
T153	TEST 7985 7987	CT
T154	TEST 7988 8016	ABDOMEN/PELVIS WITH CONTRAST
T155	PROBLEM 8074 8111	At least 6 hepatic metastatic lesions
T156	PROBLEM 8237 8319	Heterogeneous relatively well-circumscribed mass in the pancreaticoduodenal groove
T157	PROBLEM 8367 8375	The mass
T158	PROBLEM 8393 8441	exophytic pancreatic or exophytic duodenal tumor
T159	PROBLEM 8446 8494	associated pancreatic or biliary ductal dilation
T160	PROBLEM 8496 8517	Prominent lymph nodes
T161	PROBLEM 8530 8538	the mass
T162	PROBLEM 8622 8641	disease involvement
T163	PROBLEM 8660 8693	Indeterminate left adrenal nodule
T164	PROBLEM 8756 8799	benign renal cyst in the left inferior pole
T165	PROBLEM 8815 8853	Mass in the pancreaticoduodenal groove
T166	PROBLEM 8874 8894	Nonobstructive bowel
T167	PROBLEM 8899 8907	free air
T168	PROBLEM 8923 9009	Mild to moderate atherosclerotic calcification of the abdominal aorta and its branches
T169	PROBLEM 9011 9026	Lymphadenopathy
T170	PROBLEM 9028 9060	Prominent mesenteric lymph nodes
T171	PROBLEM 9096 9103	ascites
T172	PROBLEM 9171 9188	suspicious lesion
T173	TREATMENT 9219 9244	Unremarkable Lines/drains
T174	PROBLEM 9274 9356	Heterogeneous relatively well-circumscribed mass in the pancreaticoduodenal groove
T175	PROBLEM 9365 9413	associated biliary or pancreatic ductal dilation
T176	PROBLEM 9446 9466	neuroendocrine tumor
T177	PROBLEM 9471 9501	gastrointestinal stromal tumor
T178	PROBLEM 9507 9547	Aleast 6 hepatic hypoattenuating lesions
T179	TEST 9554 9570	imaging findings
T180	PROBLEM 9586 9596	metastases
T181	PROBLEM 9602 9641	Indeterminate small left adrenal nodule
T182	TEST 9674 9676	CT
T183	PROBLEM 9716 9751	3 mm lateral left upper lobe nodule
T184	PROBLEM 9775 9865	A few scattered patchy perihilar bronchovascular groundglass opacities in both upper lobes
T185	PROBLEM 9878 9894	pleural effusion
T186	PROBLEM 9912 9939	mediastinal lymphadenopathy
T187	TEST 9943 9954	CT criteria
T188	PROBLEM 9999 10019	pericardial effusion
T189	PROBLEM 10069 10097	Mild coronary calcifications
T190	PROBLEM 10122 10147	suspicious osseous lesion
T191	PROBLEM 10156 10208	Nonspecific solid 3 mmlateral left upper lobe nodule
T192	PROBLEM 10249 10332	Few nonspecific patchy peribronchovascular groundglass opacities in the upper lobes
T193	PROBLEM 10354 10366	inflammatory
T194	PROBLEM 10454 10518	a newly diagnosed metastatic adenocarcinoma of pancreatic origin
T195	PROBLEM 10528 10557	malignant biliary obstruction
T196	TREATMENT 10591 10611	endobiliary stenting
T197	TEST 10633 10654	somatic tumor testing
T198	TEST 10658 10686	the patient's tumor specimen
T199	PROBLEM 10790 10814	any actionable mutations
T200	PROBLEM 10818 10843	other genetic alterations
T201	TREATMENT 10867 10884	treatment options
T202	TREATMENT 10899 10922	already-approved agents
T203	PROBLEM 10993 11003	her cancer
T204	TREATMENT 11038 11047	treatment
T205	PROBLEM 11066 11095	stage IV (metastatic) disease
T206	TreatmentType 11114 11130	systemic therapy
T207	TreatmentType 11132 11144	chemotherapy
T208	TreatmentType 11288 11297	treatment
T209	TREATMENT 11403 11410	therapy
T210	TREATMENT 11492 11504	care options
T211	TreatmentType 11533 11554	chemotherapy regimens
T212	PROBLEM 11574 11602	metastatic pancreatic cancer
T213	TREATMENT 11623 11630	therapy
T214	PROBLEM 11683 11703	co-morbid conditions
T216	MedicationName 11805 11815	leucovorin
T217	MedicationName 11817 11827	irinotecan
T218	MedicationName 11833 11844	oxaliplatin
T219	TREATMENT 11868 11879	gemcitabine
T220	TREATMENT 11885 11899	nab-paclitaxel
T221	PerformanceStatus 11977 11987	assessment
T222	TREATMENT 12055 12066	gemcitabine
T223	TREATMENT 12071 12085	nab-paclitaxel
T224	TREATMENT 12212 12234	clinical trial options
T225	TREATMENT 12239 12263	the first-line treatment
T226	PROBLEM 12267 12295	metastatic pancreatic cancer
T227	TREATMENT 12458 12467	treatment
T228	TreatmentType 12525 12541	SoC chemotherapy
T229	TREATMENT 12700 12713	randomization
T230	TreatmentType 12724 12740	SOC chemotherapy
T231	TREATMENT 12742 12753	gemcitabine
T232	TREATMENT 12754 12757	nab
T233	TREATMENT 12758 12768	paclitaxel
T234	TREATMENT 12772 12782	FOLFIRINOX
T235	TREATMENT 12788 12815	an experimental therapy arm
T236	TREATMENT 12843 12854	gemcitabine
T237	TREATMENT 12855 12869	nab-paclitaxel
T238	TREATMENT 12875 12886	pamrevlumab
T239	TREATMENT 12888 12933	an anti-CTGF (connective tissue growth factor
T240	TEST 12935 12954	monoclonal antibody
T241	PROBLEM 12986 13015	fresh tumor tissue collection
T242	TREATMENT 13120 13147	Cancer Immunotherapy (PICI)
T243	TREATMENT 13173 13190	a platform design
T244	TREATMENT 13203 13239	test multiple different chemotherapy
T245	TREATMENT 13240 13266	immunotherapy combinations
T246	TREATMENT 13340 13351	gemcitabine
T247	TREATMENT 13352 13366	nab-paclitaxel
T248	TREATMENT 13381 13399	hydroxychloroquine
T249	TREATMENT 13401 13424	an anti-autophagy agent
T250	TREATMENT 13443 13462	low-dose ipilimumab
T251	ProcedureName 13541 13564	archived tumor material
T252	ProcedureName 13568 13596	a fresh pre-treatment biopsy
T253	TEST 13601 13621	correlative analyses
T254	TEST 13683 13701	A phase 1/1b study
T255	TEST 13714 13735	an anti-CD39 antibody
T256	TREATMENT 13763 13795	our Cancer Immunotherapy Program
T257	TREATMENT 13811 13846	a 1st-line pancreas-specific cohort
T258	TREATMENT 13853 13863	this agent
T259	TREATMENT 13903 13914	gemcitabine
T260	TREATMENT 13915 13929	nab-paclitaxel
T261	TEST 14086 14107	laboratory assessment
T262	TEST 14131 14139	her LFTs
T263	TREATMENT 14192 14209	chemotherapy ASAP
T264	PROBLEM 14252 14269	Her active cancer
T265	PROBLEM 14281 14307	a life-threatening illness
T266	PROBLEM 14318 14331	complications
T267	TREATMENT 14356 14374	patient management
T268	TREATMENT 14382 14419	the patient's systemic cancer therapy
T269	TEST 14441 14461	intensive monitoring
T270	PROBLEM 14466 14509	potential major/life-threatening toxicities
T271	Age 367 369	69
T272	ClinicalCondition 503 528	pancreatic adenocarcinoma
A1	ChronicVal T272 chronic
A2	ContinuityVal T272 unclear
T273	Histology 514 528	adenocarcinoma
T274	Metastasis 492 502	metastatic
R1	TumorDesc TumorDetails:T274 Desc:T272	
T275	PatientCharacteristics 670 688	Cantonese-speaking
T276	Datetime 727 737	06/26/2021
T277	Duration 743 751	2 months
T278	Symptom 794 808	abdominal pain
A3	IsPresentOnFirstCancerDiagnosis T278 yes
A4	IsCausedByDiagnosedCancer T278 yes
A5	ChronicVal T278 non-chronic
A6	ContinuityVal T278 new
T279	Site 768 778	epigastric
T280	Laterality 783 787	left
R2	LateralityOfSite Arg1:T280 Arg2:T279	
R3	SiteOf Arg1:T279 Arg2:T278	
R4	Temporal Arg1:T277 Arg2:T278	
T281	Symptom 828 835	wt loss
A7	IsPresentOnFirstCancerDiagnosis T281 yes
A8	IsCausedByDiagnosedCancer T281 yes
A9	ChronicVal T281 non-chronic
A10	ContinuityVal T281 unclear
A11	IsPresentOnFirstCancerDiagnosis T17 yes
A12	IsCausedByDiagnosedCancer T17 yes
A13	ChronicVal T17 non-chronic
A14	ContinuityVal T17 worsening
A15	IsPresentOnFirstCancerDiagnosis T18 yes
A16	IsCausedByDiagnosedCancer T18 yes
A17	ChronicVal T18 non-chronic
A18	ContinuityVal T18 worsening
R5	HappensBefore Arg1:T276 Arg2:T278	
R6	HappensBefore Arg1:T276 Arg2:T281	
R7	HappensBefore Arg1:T276 Arg2:T17	
R8	HappensAtOnDuring Arg1:T276 Arg2:T18	
T282	Radiology 942 971	CT scan of the abdomen/pelvis
A19	IntentVal T282 diagnosis
T283	RadPathResult 986 990	mass
A20	RadPathResultVal T283 InitialCancerDiagnosis
T284	RadPathResult 1054 1077	hypoattenuating lesions
A21	RadPathResultVal T284 InitialCancerDiagnosis
T285	Site 998 1024	pancreaticoduodenal groove
T286	Site 1046 1053	hepatic
R9	SiteOf Arg1:T286 Arg2:T284	
R10	SiteOf Arg1:T285 Arg2:T283	
R11	ResultOfTest Desc:T283 Test:T282	
R12	ResultOfTest Desc:T284 Test:T282	
T287	Metastasis 1093 1103	metastases
A22	NegationModalityVal T287 uncertain_in_present
A23	EpisodeDescription T287 FirstOccurrence
R13	TestOrProcedureReveals Test:T282 Desc:T287	
A24	TreatmentContinuityVal T25 started
A25	TreatmentTypeVal T25 others
A26	TreatmentIntentVal T25 others
A27	TreatmentCategory T25 Supportive
R14	TreatmentAdministeredForProblem Treatment:T25 Prob:T278	
T288	ProcedureName 1174 1180	biopsy
A28	NegationModalityVal T288 planned_in_future
A29	IntentVal T288 diagnosis
T289	Datetime 1203 1213	07/06/2021
R15	HappensAtOnDuring Arg1:T288 Arg2:T289	
T290	Histology 1233 1247	adenocarcinoma
A30	EpisodeDescription T290 FirstOccurrence
R16	TestOrProcedureReveals Test:T288 Desc:T290	
T291	Pathology 1249 1252;1256 1259	MMR IHC
A31	IntentVal T291 diagnosis
T292	Datetime 1331 1341	07/18/2020
T293	Symptom 1360 1374	abdominal pain
A32	IsPresentOnFirstCancerDiagnosis T293 yes
A33	IsCausedByDiagnosedCancer T293 yes
A34	ChronicVal T293 non-chronic
A35	ContinuityVal T293 worsening
R17	HappensAtOnDuring Arg1:T292 Arg2:T293	
T294	ClinicalCondition 1386 1399	elevated LFTs
A36	ChronicVal T294 non-chronic
A37	ContinuityVal T294 new
T295	Symptom 1405 1422	jaundice symptoms
A38	IsPresentOnFirstCancerDiagnosis T295 no
A39	IsCausedByDiagnosedCancer T295 yes
A40	ChronicVal T295 non-chronic
A41	ContinuityVal T295 new
T296	Symptom 1427 1439	sclericterus
A42	IsPresentOnFirstCancerDiagnosis T296 no
A43	IsCausedByDiagnosedCancer T296 yes
A44	ChronicVal T296 non-chronic
A45	ContinuityVal T296 new
R18	HappensAtOnDuring Arg1:T292 Arg2:T294	
R19	HappensAtOnDuring Arg1:T292 Arg2:T295	
R20	HappensAtOnDuring Arg1:T292 Arg2:T296	
T297	ProcedureName 1458 1462	ERCP
A46	IntentVal T297 others
A47	TreatmentTypeVal T297 others
A48	TreatmentCategory T297 Others
T298	Datetime 1477 1487	07/20/2020
T299	ProcedureName 1494 1554	placement of a 10x80 mm Evolution uncovered bare metal stent
A49	IntentVal T299 others
A50	TreatmentTypeVal T299 others
A51	TreatmentCategory T299 Others
T300	ClinicalCondition 1565 1585	high-grade stricture
A52	ChronicVal T300 non-chronic
A53	ContinuityVal T300 new
R21	TestOrProcedureConductedForProblem Test:T299 Prob:T300	
R22	TestOrProcedureReveals Test:T297 Desc:T300	
T301	Site 1593 1603	distal CBD
R23	SiteOf Arg1:T301 Arg2:T300	
T302	Radiology 1618 1621	EUS
A54	IntentVal T302 diagnosis
T303	RadPathResult 1646 1680	well circumscribed hypoechoic mass
A55	RadPathResultVal T303 InitialCancerDiagnosis
T304	Size 1634 1645	45.8x44.4mm
A56	EpisodeDescription T304 FirstOccurrence
R24	SizeOf Arg1:T304 Arg2:T303	
T305	Site 1688 1708	head of the pancreas
R25	SiteOf Arg1:T305 Arg2:T303	
R26	ResultOfTest Desc:T303 Test:T302	
T306	ProcedureName 1715 1734	additional biopsies
A57	IntentVal T306 diagnosis
T307	PerformanceStatus 1810 1845	previously independent with her ADL
A58	PerformanceStatusType T307 Other
T308	Symptom 1848 1856	Appetite
A59	IsPresentOnFirstCancerDiagnosis T308 unclear
A60	IsCausedByDiagnosedCancer T308 yes
A61	ContinuityVal T308 worsening
T309	Duration 1882 1896	past few weeks
R27	Temporal Arg1:T309 Arg2:T308	
A62	IsPresentOnFirstCancerDiagnosis T39 yes
A63	IsCausedByDiagnosedCancer T39 yes
A64	ChronicVal T39 non-chronic
A65	ContinuityVal T39 unclear
T310	Symptom 1933 1939	fevers
A66	NegationModalityVal T310 negated
T311	Symptom 1940 1946	chills
A67	NegationModalityVal T311 negated
T312	Symptom 1986 1990	pain
A68	IsPresentOnFirstCancerDiagnosis T312 yes
A69	IsCausedByDiagnosedCancer T312 yes
A70	ChronicVal T312 non-chronic
A71	ContinuityVal T312 improving
A72	TreatmentContinuityVal T42 continuing
A73	TreatmentTypeVal T42 others
A74	TreatmentIntentVal T42 others
A75	TreatmentCategory T42 Supportive
T313	MedicationName 2014 2023	oxycodone
A76	TreatmentContinuityVal T313 discontinued_early
A77	TreatmentTypeVal T313 others
A78	TreatmentIntentVal T313 others
A79	TreatmentCategory T313 Supportive
R28	TreatmentAdministeredForProblem Treatment:T42 Prob:T312	
R29	TreatmentAdministeredForProblem Treatment:T313 Prob:T312	
T314	Symptom 2065 2077	constipation
A80	NegationModalityVal T314 affirmed
A81	IsPresentOnFirstCancerDiagnosis T314 no
A82	IsCausedByDiagnosedCancer T314 no
A83	ChronicVal T314 non-chronic
A84	ContinuityVal T314 stopped
R30	TreatmentDiscontinuedBecauseOf Therapy:T313 Reason:T314	
R31	ConditionOrTreatmentCausesProblem Treatment:T313 Prob:T314	
A85	ChronicVal T46 chronic
A86	ContinuityVal T46 stable
A87	ChronicVal T47 chronic
A88	ContinuityVal T47 stable
A89	ChronicVal T48 chronic
A90	ContinuityVal T48 stable
A91	ChronicVal T49 chronic
A92	ContinuityVal T49 stable
A93	ChronicVal T51 chronic
A94	ContinuityVal T51 stable
A95	ChronicVal T52 chronic
A96	ContinuityVal T52 stable
A97	ChronicVal T53 chronic
A98	ContinuityVal T53 stable
T315	Symptom 2176 2189	low back pain
A99	IsPresentOnFirstCancerDiagnosis T315 yes
A100	IsCausedByDiagnosedCancer T315 no
A101	ChronicVal T315 chronic
A102	ContinuityVal T315 stable
T316	SectionSkip 2771 2818	Allergies/Contraindications  No Known Allergies
A103	SectionSkipType T316 allergies
T317	ClinicalCondition 2876 2882	cancer
A104	NegationModalityVal T317 negated
A105	ExperiencerVal T317 family
T318	Tobacco 2970 2982	Never Smoker
A106	NegationModalityVal T318 negated
T319	Alcohol 3066 3079	Not Currently
A107	NegationModalityVal T319 negated
T320	Drugs 3094 3099	Never
A108	NegationModalityVal T320 negated
T321	LivingCondition 3115 3152	husband at home in *****; 3 children.
A109	IsStoppedOrContinuing T321 continuing
T322	MaritalStatus 3115 3122	husband
A110	IsStoppedOrContinuing T322 continuing
T323	PerformanceStatus 3185 3186	2
A111	PerformanceStatusType T323 ECOG
T324	SectionSkip 3190 3910;3913 3957	PHYSICAL EXAM via video observation:   Vitals: Not performed as today's visit was conducted via video  Constitutional: Ill-appearing. Not diaphoretic.  Head: Normocephalic, atraumatic. External ears normal. Nose normal.    Eyes: Extraocular movements intact. Conjunctivae normal. No eye discharge. Cannot appreciate scleral icterus.  Neck: Normal range of motion.   Pulmonary/Chest: Normal effort. No respiratory distress. No cough.  GI: No abdominal distention.   Musculoskeletal: No apparent edema.   Skin: Not jaundiced. Not pale. No visible erythema. No visible rash.  Neurological: Alert and oriented to person, place and time. Able to stand from sitting and walk.   Psychiatric: Normal mood and affect. Behavior is normal. Judgment and thought content normal.
A112	SectionSkipType T324 physical_exam
T325	SectionSkip 4761 5885;5888 7815;7818 9759;9762 10367	I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:    Result Date: 07/18/2021  CT ABDOMEN/PELVIS  FINDINGS:  Visualized lung bases:  Bibasilar atelectasis    Liver:  Slightly increased size of some of the hypoattenuating/hypoenhancing lesions in the liver. Other lesions are not significant changed. Index lesions as below.    INDEX LESIONS (Restaging):   AI1:  Hepatic segment 5 lesion : 1.7 x 1.3 cm (Se/Im September 43), previously 1.7 x 1.3 cm   AI2:  Hepatic segment 6 lesion : 0.9 x 0.7 cm (Se/Im September 53), previously 0.4 x 0.3 cm   AI3:  Hepatic segment December 23 lesion : 1.0 x 0.9 cm (Se/Im September 39), previously 0.7 x 0.4 cm     Additionally, a few new small lesions, for example the lesion in hepatic segment 5 measuring up to 0.8 cm (series 3 image 47).    Gallbladder/bile ducts: Distended gallbladder measuring up to 4.7 cm in diameter, but without significant associated inflammatory changes.    New mild intrahepatic/extra hepatic biliary ductal dilatation with abrupt caliber change at the mass centered in the pancreaticoduodenal groove.    Spleen:  Unremarkable    Pancreas:  Increased size of the heterogeneously enhancing mass centered in the pancreaticoduodenal groove, now measuring approximately 4.5 cm x 3.7 cm x 7.5 cm (series 3 image 71, series 602 image 55). Mass extends into the distal aspects of the common bile duct (series 602 image 55). Increased associated mild pancreatic ductal dilatation.    New mild peripancreatic fat stranding and mild pancreatic parenchymal edema throughout the remaining pancreas.     Adrenal Glands:  Similar small left adrenal nodule measuring up to 1.1 cm (series 3 image 41).    Kidneys:  Similar subcentimeter hypoattenuating foci, too small to fully characterize, but likely benign.     GI Tract:  Unremarkable    Vasculature:  Similar atherosclerosis.    Lymphadenopathy: Increased size of multiple upper abdominal and mesenteric lymph nodes, some of which are centrally cystic/necrotic, for example the superior mesenteric lymph node now measuring approximately 1.5 cm x 1.2 cm) series 3 image 78) previously 1.3 cm x 0.9 cm, and the portal caval lymph node now measuring approximately 2.2 cm x 1.2 cm (series 3 image 57) previously 1.4 cm x 0.9 cm.    Peritoneum: No ascites    Bladder: Distended    Reproductive organs: Unremarkable    Bones:  Similar multilevel spondylosis. Similar degenerative changes of the hips, sacroiliac joints, and pelvis.    Extraperitoneal soft tissues: Unremarkable    Lines/drains/medical devices: None    IMPRESSION:   1. Compared to 06/26/2021, increased size of the primary malignancy centered at the pancreaticoduodenal groove. Increased size and number of hepatic and nodal metastases.    2. New mild biliary ductal and gallbladder dilatation, likely due to worsening biliary obstruction.    3. New mild pancreatic ductal dilatation, mild peripancreatic fat stranding, and mild pancreatic parenchymal edema. Overall, findings are most compatible with acute interstitial edematous pancreatitis from pancreatic ductal obstruction.    4. Similar small left adrenal nodule.        Result Date: 06/27/2021  CT ABDOMEN/PELVIS WITH CONTRAST   FINDINGS: Visualized lung bases:  Unremarkable Liver:  At least 6 hepatic metastatic lesions with largest in the gallbladder fossa 2.4 cm (series 8, image 38). Gallbladder: Unremarkable Spleen:  Unremarkable Pancreas: Heterogeneous relatively well-circumscribed mass in the pancreaticoduodenal groove measuring 3 3.7 x 3.4 cm (series 8, image 59). The mass likely represent exophytic pancreatic or exophytic duodenal tumor. No associated pancreatic or biliary ductal dilation. Prominent lymph nodes adjacent to the mass measuring up to 9 mm (series 8, image 57) which is nonspecific but could represent disease involvement. Adrenal Glands:  Indeterminate left adrenal nodule measuring up to 1.1 cm (series 8, image 34). Kidneys:  Likely benign renal cyst in the left inferior pole.    GI Tract:  Mass in the pancreaticoduodenal groove as described above. Nonobstructive bowel. No free air. Vasculature:  Mild to moderate atherosclerotic calcification of the abdominal aorta and its branches. Lymphadenopathy: Prominent mesenteric lymph nodes as described above. Peritoneum: No ascites Bladder: Unremarkable Reproductive organs: Unremarkable Bones:  No suspicious lesion Extraperitoneal soft tissues: Unremarkable Lines/drains/medical devices: None    1.  Heterogeneous relatively well-circumscribed mass in the pancreaticoduodenal groove without associated biliary or pancreatic ductal dilation. Differential diagnoses include neuroendocrine tumor and gastrointestinal stromal tumor. 2.  Aleast 6 hepatic hypoattenuating lesions, with imaging findings suspicious for metastases. 3.  Indeterminate small left adrenal nodule.       Result Date: 06/28/2021  CT CHEST WITH CONTRAST   FINDINGS: LUNGS: 3 mm lateral left upper lobe nodule (series August 270). A few scattered patchy perihilar bronchovascular groundglass opacities in both upper lobes. PLEURA: No pleural effusion. MEDIASTINUM: No mediastinal lymphadenopathy by CT criteria. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. Normal caliber of the ascending thoracic aorta. Mild coronary calcifications. BONES/SOFT TISSUES: No suspicious osseous lesion.     1. Nonspecific solid 3 mmlateral left upper lobe nodule (series 2 image 100), indeterminate. 2. Few nonspecific patchy peribronchovascular groundglass opacities in the upper lobes, possibly infectious/inflammatory.
A113	SectionSkipType T325 radiology_report
T326	Age 10434 10436	69
T327	ClinicalCondition 10483 10518	adenocarcinoma of pancreatic origin
A114	ChronicVal T327 chronic
A115	ContinuityVal T327 new
T328	Metastasis 10472 10482	metastatic
A116	EpisodeDescription T328 FirstOccurrence
R32	TumorDesc TumorDetails:T328 Desc:T327	
T329	Histology 10483 10497	adenocarcinoma
A117	EpisodeDescription T329 FirstOccurrence
T330	ClinicalCondition 10538 10557	biliary obstruction
A118	ChronicVal T330 non-chronic
A119	ContinuityVal T330 stopped
R33	ConditionOrTreatmentCausesProblem Treatment:T327 Prob:T330	
T331	ProcedureName 10591 10611	endobiliary stenting
A120	IntentVal T331 others
A121	TreatmentTypeVal T331 others
A122	TreatmentCategory T331 Others
R34	TestOrProcedureConductedForProblem Test:T331 Prob:T330	
T332	GenomicTest 10633 10654	somatic tumor testing
A123	NegationModalityVal T332 planned_in_future
A124	IntentVal T332 others
A125	GenomicTestType T332 Somatic
T333	GenomicTest 10743 10750	UCSF500
A126	NegationModalityVal T333 planned_in_future
A127	GenomicTestType T333 Somatic
T334	GenomicTestResult 10794 10814	actionable mutations
A128	GenomicTestType T334 Somatic
R35	ResultOfTest Desc:T334 Test:T333	
R36	ResultOfTest Desc:T334 Test:T332	
T335	GenomicTestResult 10824 10843	genetic alterations
A129	GenomicTestType T335 Somatic
A130	NegationModalityVal T334 hypothetical_in_future
A131	NegationModalityVal T335 hypothetical_in_future
T336	TreatmentType 10899 10922	already-approved agents
A132	NegationModalityVal T336 hypothetical_in_future
A133	TreatmentTypeVal T336 maintenance
A134	TreatmentIntentVal T336 palliative
T337	ClinicalTrial 10944 10960	clinical trials.
A135	NegationModalityVal T337 hypothetical_in_future
R37	InclusionCriteriaFor Arg1:T334 Arg2:T336	
R38	InclusionCriteriaFor Arg1:T334 Arg2:T337	
R39	InclusionCriteriaFor Arg1:T335 Arg2:T336	
R40	InclusionCriteriaFor Arg1:T335 Arg2:T337	
T338	ClinicalCondition 10997 11003	cancer
A136	ChronicVal T338 non-chronic
A137	ContinuityVal T338 new
T339	Stage 11072 11074	IV
A138	EpisodeDescription T339 FirstOccurrence
T340	Metastasis 11076 11086	metastatic
A139	EpisodeDescription T340 FirstOccurrence
R41	TumorDesc TumorDetails:T340 Desc:T338	
R42	TumorDesc TumorDetails:T339 Desc:T338	
A140	NegationModalityVal T206 hypothetical_in_future
A141	TreatmentTypeVal T206 maintenance
A142	TreatmentIntentVal T206 palliative
A143	NegationModalityVal T207 hypothetical_in_future
A144	TreatmentTypeVal T207 maintenance
A145	TreatmentIntentVal T207 palliative
A146	NegationModalityVal T208 hypothetical_in_future
A147	TreatmentTypeVal T208 maintenance
A148	TreatmentIntentVal T208 palliative
A149	NegationModalityVal T211 hypothetical_in_future
A150	TreatmentTypeVal T211 maintenance
A151	TreatmentIntentVal T211 palliative
T341	ClinicalCondition 11585 11602	pancreatic cancer
A152	ChronicVal T341 non-chronic
A153	ContinuityVal T341 new
T342	Metastasis 11574 11584	metastatic
A154	EpisodeDescription T342 FirstOccurrence
R43	TumorDesc TumorDetails:T342 Desc:T341	
T215	MedicationRegimen 11767 11777	FOLFIRINOX
A155	NegationModalityVal T215 hypothetical_in_future
A156	TreatmentTypeVal T215 maintenance
A157	TreatmentIntentVal T215 palliative
T343	MedicationRegimen 11868 11899	gemcitabine plus nab-paclitaxel
A158	NegationModalityVal T343 hypothetical_in_future
A159	TreatmentTypeVal T343 maintenance
A160	TreatmentIntentVal T343 palliative
T344	MedicationName 11799 11803	5-FU
A161	NegationModalityVal T344 hypothetical_in_future
A162	TreatmentTypeVal T344 maintenance
A163	TreatmentIntentVal T344 palliative
A164	TreatmentCategory T344 AntiNeoPlastics
A165	NegationModalityVal T216 hypothetical_in_future
A166	TreatmentTypeVal T216 maintenance
A168	TreatmentCategory T216 Supportive
A169	NegationModalityVal T217 hypothetical_in_future
A170	TreatmentTypeVal T217 maintenance
A171	TreatmentIntentVal T217 palliative
A172	TreatmentCategory T217 AntiNeoPlastics
A173	NegationModalityVal T218 hypothetical_in_future
A174	TreatmentTypeVal T218 maintenance
A175	TreatmentIntentVal T218 palliative
A176	TreatmentCategory T218 AntiNeoPlastics
R44	RegimenFor Arg1:T216 Arg2:T215	
R45	RegimenFor Arg1:T344 Arg2:T215	
R46	RegimenFor Arg1:T217 Arg2:T215	
R47	RegimenFor Arg1:T218 Arg2:T215	
T345	MedicationRegimen 12055 12085	gemcitabine and nab-paclitaxel
A167	NegationModalityVal T345 hypothetical_in_future
A177	TreatmentTypeVal T345 maintenance
A178	TreatmentIntentVal T345 palliative
T346	ClinicalTrial 12212 12226	clinical trial
A179	NegationModalityVal T346 hypothetical_in_future
T347	TreatmentType 12243 12263	first-line treatment
A180	NegationModalityVal T347 hypothetical_in_future
A181	TreatmentTypeVal T347 maintenance
A182	TreatmentIntentVal T347 palliative
R48	InclusionCriteriaFor Arg1:T346 Arg2:T347	
T348	ClinicalCondition 12278 12295	pancreatic cancer
A183	ContinuityVal T348 new
T349	Metastasis 12267 12277	metastatic
A184	EpisodeDescription T349 FirstOccurrence
R49	TumorDesc TumorDetails:T349 Desc:T348	
R50	InclusionCriteriaFor Arg1:T348 Arg2:T346	
A185	NegationModalityVal T230 hypothetical_in_future
A186	TreatmentTypeVal T230 maintenance
A187	TreatmentIntentVal T230 palliative
T350	MedicationRegimen 12742 12768	gemcitabine/nab-paclitaxel
A188	NegationModalityVal T350 hypothetical_in_future
A189	TreatmentTypeVal T350 maintenance
A190	TreatmentIntentVal T350 palliative
T351	MedicationRegimen 12772 12782	FOLFIRINOX
A191	NegationModalityVal T351 hypothetical_in_future
A192	TreatmentTypeVal T351 maintenance
A193	TreatmentIntentVal T351 palliative
A194	NegationModalityVal T228 hypothetical_in_future
A195	TreatmentTypeVal T228 maintenance
A196	TreatmentIntentVal T228 palliative
T352	ClinicalTrial 12553 12585	Precision Promise clinical trial
A197	NegationModalityVal T352 hypothetical_in_future
T353	MedicationRegimen 12843 12886	gemcitabine/nab-paclitaxel plus pamrevlumab
A198	NegationModalityVal T353 hypothetical_in_future
A199	TreatmentTypeVal T353 maintenance
A200	TreatmentIntentVal T353 palliative
T354	ClinicalTrial 12843 12886	gemcitabine/nab-paclitaxel plus pamrevlumab
A201	NegationModalityVal T354 hypothetical_in_future
T355	ProcedureName 12986 13015	fresh tumor tissue collection
A202	NegationModalityVal T355 hypothetical_in_future
A203	IntentVal T355 others
A204	TreatmentTypeVal T355 others
R51	InclusionCriteriaFor Arg1:T355 Arg2:T352	
T356	ClinicalTrial 13053 13074	REVOLUTION (PICI0044)
T357	TreatmentType 13227 13239	chemotherapy
A205	NegationModalityVal T357 hypothetical_in_future
A206	TreatmentTypeVal T357 others
A207	TreatmentIntentVal T357 others
T358	TreatmentType 13239 13253	/immunotherapy
A208	NegationModalityVal T358 hypothetical_in_future
A209	TreatmentTypeVal T358 others
A210	TreatmentIntentVal T358 others
T359	ClinicalTrial 13340 13399;13443 13462	gemcitabine/nab-paclitaxel together with hydroxychloroquine low-dose ipilimumab
A211	NegationModalityVal T359 hypothetical_in_future
T360	MedicationRegimen 13340 13399;13443 13462	gemcitabine/nab-paclitaxel together with hydroxychloroquine low-dose ipilimumab
A214	NegationModalityVal T360 hypothetical_in_future
A212	TreatmentTypeVal T360 maintenance
A213	TreatmentIntentVal T360 palliative
A215	NegationModalityVal T251 hypothetical_in_future
A216	IntentVal T251 others
A217	NegationModalityVal T252 hypothetical_in_future
A218	IntentVal T252 others
R52	InclusionCriteriaFor Arg1:T251 Arg2:T356	
R53	InclusionCriteriaFor Arg1:T252 Arg2:T356	
R54	InclusionCriteriaFor Arg1:T251 Arg2:T359	
R55	InclusionCriteriaFor Arg1:T252 Arg2:T359	
T361	ClinicalTrial 13685 13736;13903 13929	phase 1/1b study of TTX-030 (an anti-CD39 antibody) gemcitabine/nab-paclitaxel
A219	NegationModalityVal T361 hypothetical_in_future
T362	ClinicalCondition 13813 13839	1st-line pancreas-specific
R56	InclusionCriteriaFor Arg1:T362 Arg2:T361	
T363	TreatmentType 14192 14204	chemotherapy
A220	NegationModalityVal T363 planned_in_future
A221	TreatmentContinuityVal T363 planned
A222	TreatmentTypeVal T363 maintenance
A223	TreatmentIntentVal T363 palliative
R57	HappensAtOnDuring Arg1:T298 Arg2:T297	
R58	HappensAtOnDuring Arg1:T298 Arg2:T299	
R59	HappensAtOnDuring Arg1:T298 Arg2:T302	
R60	TestOrProcedureReveals Test:T302 Desc:T304	
R61	InclusionCriteriaFor Arg1:T341 Arg2:T211	
R62	InclusionCriteriaFor Arg1:T342 Arg2:T211	
R64	InclusionCriteriaFor Arg1:T341 Arg2:T215	
R63	InclusionCriteriaFor Arg1:T341 Arg2:T345	
A224	PerformanceStatusType T221 Other
R65	InclusionCriteriaFor Arg1:T345 Arg2:T221	
R66	ExclusionCriteriaFor Arg1:T215 Arg2:T221	
R67	InclusionCriteriaFor Arg1:T348 Arg2:T228	
T364	hpi_start 352 354	Ms
T365	hpi_end 2065 2078	constipation.
T366	ap_start 10374 10384	Impression
T367	ap_end 14499 14510	toxicities.
